Quotes 5-day view Delayed Swiss Exchange
02/22/2021
02/23/2021
02/24/2021
02/25/2021
02/26/2021
Date
79.1(c)
78.34(c)
79.37(c)
79.04(c)
79.68 Last
5 524 873
4 947 349
4 717 956
4 747 630
1 148 424 Volume
-0.19% -0.96% +1.31% -0.42% +0.81% Change
Sales 2021
52 312 M - -
Net income 2021
10 140 M - -
Net Debt 2021
22 232 M - -
P/E ratio 2021
18,7x
Yield 2021
3,77%
Sales 2022
54 323 M - -
Net income 2022
11 255 M - -
Net Debt 2022
16 837 M - -
P/E ratio 2022
17,2x
Yield 2022
3,90%
Capitalization
197 B 197 B -
EV / Sales 2021
4,19x
EV / Sales 2022
3,93x
Nbr of Employees
105 794
Free-Float
85,6%
Novartis is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical products (79.5%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal disorders, cancers, central nervous system disorders, hormone imbalances, etc.;
- generic drugs (20.5%; Sandoz).
Net sales...
Notations Surperformance© of Novartis AG
Trading Rating : Investor Rating :
All news about NOVARTIS AG
News in other languages on NOVARTIS AG
Analyst Recommendations on NOVARTIS AG
Wanted: More high-tech manufacturing space for a global vaccine push
NOVARTIS AG
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends NOVARTIS AG
Short Term Mid-Term Long Term Trends Bearish Bullish Neutral
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
25
Average target price
109,16 $
Last Close Price
87,26 $
Spread / Highest target
70,7%
Spread / Average Target
25,1%
Spread / Lowest Target
3,14%
Please enable JavaScript in your browser's settings to use dynamic charts.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
